Acceleron Pharma Inc.
ALK7 ANTAGONISTS AND USES THEREOF

Last updated:

Abstract:

In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these ALK7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.

Status:
Application
Type:

Utility

Filling date:

22 Mar 2019

Issue date:

13 Feb 2020